GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fujian Cosunter Pharmaceutical Co 300436.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

75.72

-0.01%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥416.4m

FY2016FY2025

Net income

−CN¥217.8m

FY2016FY2025

Free cash flow

−CN¥94.6m

FY2016FY2025

Shareholders' equity

CN¥277.5m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥416.4mCN¥441.5mCN¥422.7mCN¥385.8mCN¥370.4mCN¥368.5mCN¥414.9mCN¥402.4mCN¥296.1mCN¥312.9m
Research and developmentCN¥31.8mCN¥44.1mCN¥133.0mCN¥185.5mCN¥69.0mCN¥47.5mCN¥53.2mCN¥69.7mCN¥58.9mCN¥60.8m
Operating income−CN¥85.9m−CN¥164.5m−CN¥267.3m−CN¥225.0m−CN¥81.1mCN¥22.9mCN¥12.5mCN¥12.0mCN¥37.0mCN¥69.8m
Net income−CN¥217.8m−CN¥156.3m−CN¥348.6m−CN¥127.4m−CN¥34.9mCN¥14.8mCN¥10.7mCN¥16.5mCN¥33.6mCN¥66.4m
Diluted earnings per share-1.37-0.98-2.19-0.80-0.220.110.080.120.240.47

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.40bnCN¥1.44bnCN¥1.61bnCN¥1.49bnCN¥1.45bnCN¥1.01bnCN¥896.3mCN¥854.7mCN¥736.5mCN¥700.7m
Cash and short-term investments—CN¥144.0mCN¥202.8mCN¥239.0mCN¥393.6mCN¥136.0mCN¥93.7mCN¥85.9mCN¥408.1mCN¥464.9m
Total liabilitiesCN¥1.05bnCN¥1.04bnCN¥1.05bnCN¥539.2mCN¥396.9mCN¥424.1mCN¥322.5mCN¥292.3mCN¥184.4mCN¥148.3m
DebtCN¥244.1mCN¥324.5mCN¥387.0mCN¥293.4mCN¥124.8mCN¥211.3mCN¥134.9mCN¥58.1mCN¥56.9mCN¥59.9m
Shareholders' equityCN¥277.5mCN¥360.2mCN¥516.5mCN¥928.5mCN¥1.04bnCN¥576.6mCN¥563.6mCN¥554.0mCN¥552.0mCN¥552.4m
Shares outstanding159m159m159m159m159m140m140m137m140m141m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−CN¥35.1mCN¥20.7m−CN¥174.6m−CN¥119.7m−CN¥17.8mCN¥15.6mCN¥34.0mCN¥10.9mCN¥71.5mCN¥73.8m
Capital spending−CN¥59.5m−CN¥67.0m−CN¥201.2m−CN¥196.0m−CN¥174.4m−CN¥54.5m−CN¥67.8m−CN¥229.3m−CN¥35.6m−CN¥82.5m
Free cash flow−CN¥94.6m−CN¥46.3m−CN¥375.8m−CN¥315.6m−CN¥192.2m−CN¥38.9m−CN¥33.8m−CN¥218.3mCN¥35.9m−CN¥8.7m
Dividends paid−CN¥15.4m−CN¥17.4m−CN¥17.4m−CN¥10.4m−CN¥9.2m−CN¥8.8m−CN¥7.4m−CN¥15.2m−CN¥35.4m−CN¥35.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥121.7mCN¥98.4mCN¥100.5mCN¥104.8mCN¥111.2mCN¥97.6mCN¥115.1mCN¥108.1m
Operating income−CN¥21.0m−CN¥16.9m−CN¥18.7m−CN¥36.6m−CN¥33.7m−CN¥27.2m−CN¥96.4m−CN¥27.1m
Net income−CN¥42.2m−CN¥25.9m−CN¥106.3m−CN¥44.9m−CN¥38.2m−CN¥28.5m−CN¥85.7m−CN¥34.6m
Diluted earnings per share-0.27-0.16-0.67-0.28-0.24-0.18-0.54-0.22
Cash from operations———−CN¥25.0m−CN¥6.0m−CN¥12.0mCN¥38.0mCN¥5.0m
Capital spending−CN¥14.0m−CN¥12.0m−CN¥31.0m−CN¥13.0m−CN¥3.0m−CN¥11.0m−CN¥20.0m−CN¥11.0m
Free cash flow———−CN¥38.0m−CN¥9.0m−CN¥23.0mCN¥18.0m−CN¥6.0m
Total assetsCN¥1.34bnCN¥1.41bnCN¥1.40bnCN¥1.52bnCN¥1.37bnCN¥1.38bnCN¥1.44bnCN¥1.51bn
Cash and short-term investments———CN¥245.2mCN¥82.4mCN¥119.5mCN¥144.0mCN¥127.3m
DebtCN¥181.1mCN¥241.1mCN¥244.1mCN¥255.3mCN¥290.1mCN¥311.9mCN¥324.5mCN¥411.9m
Shareholders' equityCN¥209.4mCN¥251.6mCN¥277.5mCN¥383.0mCN¥292.7mCN¥331.7mCN¥360.2mCN¥445.8m

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-20.6%-37.3%-63.2%-58.3%-21.9%6.2%
Net margin-52.3%-35.4%-82.5%-33.0%-9.4%4.0%
Return on equity-78.5%-43.4%-67.5%-13.7%-3.3%2.6%
Return on assets-15.6%-10.9%-21.6%-8.5%-2.4%1.5%
Free cash flow yield0.2%0.7%0.2%0.6%1.2%0.6%
Revenue growth-5.7%4.4%9.6%4.1%0.5%-11.2%
Earnings growth39.4%-55.2%173.6%265.2%-335.3%38.0%
Current ratio1.08x0.71x0.75x0.97x1.82x0.87x
Debt to equity0.88x0.90x0.75x0.32x0.12x0.37x
Equity ratio19.8%25.0%32.0%62.1%72.1%57.3%
Interest coverage-2.62x-4.62x-7.63x-20.97x-8.78x2.54x
R&D as a share of sales7.6%10.0%31.5%48.1%18.6%12.9%
Buybacks as a share of market value0.0%-0.0%0.0%-0.3%-13.4%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.6%2.5%3.0%
Operating income-27.4%——
Net income19.6%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-29.2%-44.6%-33.3%-13.4%
Net margin-43.6%-51.0%-36.2%-15.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-65.2-33.3-11.7-49.0-218.6364.9434.3202.1122.4115.0
Price to sales34.111.89.716.220.614.711.28.313.924.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 4 May 2018.

FY2018FY2017FY2016
Paid in the year0.100.250.25
  • 2-for-1 split · 16 Sept 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.